Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial.
anticoagulation
arrhythmia
dabigatran
risk scores
rivaroxaban
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Apr 2021
19 Apr 2021
Historique:
received:
07
03
2021
revised:
31
03
2021
accepted:
15
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Data from the CRAFT trial (NCT02987062) were included. The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period. Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group. Higher rate of MAEs and its components was observed in patients on VKA followed by rivaroxaban as compared to patients on dabigatran (43% vs. 42% vs. 31%, Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores.
METHODS
METHODS
Data from the CRAFT trial (NCT02987062) were included. The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period.
RESULTS
RESULTS
Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group. Higher rate of MAEs and its components was observed in patients on VKA followed by rivaroxaban as compared to patients on dabigatran (43% vs. 42% vs. 31%,
CONCLUSIONS
CONCLUSIONS
Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events.
Identifiants
pubmed: 33921867
pii: jcm10081780
doi: 10.3390/jcm10081780
pmc: PMC8073861
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204
pubmed: 24055744
Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):8-14
pubmed: 25587093
Am J Med. 2018 May;131(5):574.e13-574.e27
pubmed: 29274754
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
Am J Cardiol. 2017 Nov 15;120(10):1813-1819
pubmed: 28864318
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Stroke. 2017 Jun;48(6):e149
pubmed: 28455316
Thromb Haemost. 2016 Oct 28;116(5):975-986
pubmed: 27538358
Chest. 2016 Dec;150(6):1302-1312
pubmed: 27938741
J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Eur Heart J. 2019 May 14;40(19):1492-1500
pubmed: 30590440
Int J Stroke. 2017 Aug;12(6):589-596
pubmed: 28730948
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
BMC Cardiovasc Disord. 2015 Nov 19;15:156
pubmed: 26584938
Kardiol Pol. 2018;76(5):889-898
pubmed: 29350386
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46
pubmed: 22575324
JAMA Intern Med. 2016 Nov 1;176(11):1662-1671
pubmed: 27695821
BMJ. 2016 Jun 16;353:i3189
pubmed: 27312796
J Am Heart Assoc. 2016 Jun 13;5(6):
pubmed: 27412905
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
Chin Med J (Engl). 2018 Jul 20;131(14):1639-1644
pubmed: 29998881